Sustained Increase in the Oral Bioavailability of Loperamide after a Single Oral Dose of HM30181, a P-glycoprotein Inhibitor, in Healthy Male Participants

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 6, 2013, Pages 419-424

  Cha, Yu Jung ^a   Lee, Howard ^a   Gu, Namyi ^a   Kim, Tae Eun ^a   Lim, Kyoung S ^a   Yoon, Seo H ^a   Chung, Jae Yong ^a   Jang, In Jin ^a   Shin, Sang Goo ^a   Yu, Kyung Sang ^a   Cho, Joo Youn ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P INHIBITOR; HM 30181; LOPERAMIDE; UNCLASSIFIED DRUG; 4-OXO-4H-CHROMENE-2-CARBOXYLIC ACID (2-(2-(4-(2-(6,7-DIMETHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHYL)-PHENYL)-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL)AMIDE; BENZOPYRAN DERIVATIVE; ISOQUINOLINE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONSTIPATION; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOGLINEAR MODEL; MALE; MOUTH MUCOSA EROSION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; BENZOPYRANS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; ISOQUINOLINES; LOPERAMIDE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; TETRAZOLES; YOUNG ADULT;

EID: 84887822047     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12108     Document Type: Article

References (21)

1. Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition. Curr Drug Metab 2011;12:722-31.
2. Canaparo R, Nordmark A, Finnstrom N, Lundgren S, Seidegard J, Jeppsson B et al. Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic Clin Pharmacol Toxicol 2007;100:240-8.
3. Kanaan M, Daali Y, Dayer P, Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol. Basic Clin Pharmacol Toxicol 2009;105:199-206.
4. Velingkar VS, Dandekar VD. Modulation of P-glycoprotein mediated multidrug resistance (MDR) in cancer using chemosensitizers. Int J Pharma Sci Res 2010;1:104-11.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer. Nat Rev Cancer 2002;2:48-58.
6. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Eur J Pharm Sci 2000;11:265-83.
7. Thomas H, Coley HM. Overcoming multidrug resistance in cancer. Cancer Control 2003;10:159-65.
8. Kim TE, Gu N, Yoon SH, Cho JY, Park KM, Shin SG et al. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers. Clin Ther 2012;34:482-94.
9. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 2010;627:92-8.
10. Center for Drug Evaluation and Research. The US Food and Drug Administration. Guidance for industry. Drug Interaction Studies - February 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (last accessed on 24 July 2013).
11. Kim T, Lee S, Shin H, Shin S, Jang I, Park KM et al. HM30181A, a novel P-glycoprotein inhibitor, increases loperamide bioavailability in healthy volunteers. Clin Pharmacol Ther 2009;85:S27.
12. Killinger JM, Weintraub HS, Fuller BL. Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. J Clin Pharmacol 1979;19:211-8.
13. Choi YH, Oh S, Yoon S, Kim T, Gu N, Kim EY et al. Simultaneous LC-MS-MS determination of HM30181A, [2-(2-{4-[2-(6, 7-Dimethoxy-3, 4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4, 5-dimethoxyphenyl]amide, as a new p-glycoprotein inhibitor and its two metabolites, M1 and M2, in human plasma. Chromatographia 2011;73:273-80.
14. Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood) 2005;230:118-27.
15. Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv 2010;17:419-25.
16. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001;84:42-7.
17. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929-37.
18. Keppler D, Kamisako T, Leier I, Cui Y, Nies AT, Tsujii H et al. Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. Adv Enzyme Regul 2000;40:339-49.
19. Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 2004;60:575-81.
20. Baker DE. Loperamide. Rev Gastroenterol Disord 2007;7(Suppl 3):S11-8.
21. Kannan P, Brimacombe KR, Zoghbi SS, Liow JS, Morse C, Taku AK et al. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos 2010;38:917-22.